Axa’s Arcturus Therapeutics ARCT Stock Holding History

Axa’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-44,206	Closed	-$1.49M	–	1064
2024 Q1	$1.49M	Buy	+44,206	New	+$1.57M	﹤0.01%	797

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Axa's ARCT Position: Q2 2024 in Review

Axa sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 44,206 shares — an estimated $1.49M sold.

Axa first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $1.49M in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

Axa reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
Axa sold 44,206 Arcturus Therapeutics shares in Q2 2024, an estimated $1.49M.
Axa first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
Axa's Arcturus Therapeutics position peaked at $1.49M in Q1 2024.
170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.